Raw_Data_Long-circulating liposomes co-delivering amphotericin B and retinoic acid for cutaneous leishmaniasis treatment

This dataset contains raw pharmacokinetic and quantitative PCR (qPCR) data from the evaluation of a novel PEGylated liposomal formulation (LAmB-RA) co-encapsulating amphotericin B (AmB) and retinoic acid (RA), an immunomodulator, for the treatment of cutaneous leishmaniasis. For comparison, other liposomal formulations were also prepared: LAmB (AmB alone), LRA (RA alone), and LEmpty (empty liposomes without any drug).Pharmacokinetic data were obtained following a single intravenous dose of 1 mg/kg AmB in female Swiss mice (4–6 weeks). Animals were assigned to three groups (LAmB, LAmB-RA, and AmBisome), and blood and liver samples were collected at 5 min, 0.5 h, 1 h, 4 h, and 24 h post-injection (n = 5/time point). Samples were stored at −80 °C and analyzed by high-performance liquid chromatography Vanquish Flex (Thermo Scientific) coupled to a mass spectrometer (LC-MS/MS).Efficacy data, in turn, were assessed in two murine infection models of cutaneous leishmaniasis:<b><i>L. major</i></b><b> (MHOM/PT/92/CRE26):</b> Female BALB/c mice were infected subcutaneously at the base of the tail. After lesion development, animals were divided into six groups (n = 8 for each group, and n = 10 for Control) and treated intraperitoneally every 2 days for 18 days. Groups included: Control (untreated), LEmpty, LRA (0.25 mg/kg), LAmB (5 mg/kg), LAmB-RA (5 mg AmB/kg + 0.25 mg RA/kg), and AmBisome (5 mg/kg).<b><i>L. amazonensis</i></b><b> (IFLA/BR/1967/PH8):</b> BALB/c mice were infected subcutaneously at the tail’s base and treated every 2 days for 24 days. Prior to treatment, animals were divided into five groups (n = 7 per group): Control (untreated), LEmpty, LAmB (5 mg/kg), LAmB-RA (5 mg AmB/kg + 0.25 mg RA/kg), and AmBisome (5 mg/kg)Treatment efficacy was evaluated by qPCR to determine parasite burden in lesions or spleen, three days after the last dose. The results support LAmB-RA as a promising therapeutic candidate for cutaneous leishmaniasis, combining prolonged circulation with enhanced <i>in vivo</i> efficacy.